4 Combinations of immune checkpoint inhibitors with fractionated radiotherapy or DNA damage response agents leads to improved anti-tumour responses and modulates the tumour immune microenvironment

• Emily Wright,
• Stewart Brown,
• Lorraine Mooney,
• Charlotte Bell,
• Nick Moore,
• Theoni Katopodi,
• Yin Xin Ho,
• Lyndsey Hanson,
• Amy Cantrell,
• Jane Kendrew,
• Pablo Binder,
• Tobias Bunday,
• Paul Farrington,
• Shannon Sharman

Affiliations

Emily Wright

Sygnature Discovery, Alderley Edge, Greater Manchester, UK

Stewart Brown

Taunton and Somerset NHS Foundation Trust

Lorraine Mooney

Aff2 Bioscience, Oncology, IMED Biotech Unit AstraZeneca Alderley Park, Alderley Edge SK10 4TG Macclesfield UK

Charlotte Bell

Clinic 275, Royal Adelaide Hospital, Adelaide, South Australia, Australia

Nick Moore

International Initiative for Impact Evaluation, London, UK

Theoni Katopodi

Sygnature Discovery, Alderley Edge, Greater Manchester, UK

Yin Xin Ho

Sygnature Discovery, Alderley Edge, Greater Manchester, UK

Lyndsey Hanson

Sygnature Discovery, Alderley Edge, Greater Manchester, UK

Amy Cantrell

Sygnature Discovery, Alderley Edge, Greater Manchester, UK

Jane Kendrew

Sygnature Discovery, Alderley Edge, Greater Manchester, UK

Pablo Binder

Sygnature Discovery, Alderley Edge, Greater Manchester, UK

Tobias Bunday

Sygnature Discovery, Alderley Edge, Greater Manchester, UK

Paul Farrington

Sygnature Discovery, Alderley Edge, Greater Manchester, UK

Shannon Sharman

Sygnature Discovery, Alderley Edge, Greater Manchester, UK